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Abstract 
 
   Src-family kinases, cytoplasmic enzymes that participate in various signaling events, are 
found at not only the plasma membrane but also subcellular compartments, such as the 
nucleus, the Golgi apparatus and late endosomes/lysosomes. Lyn, a member of the Src-family 
kinases, is known to play a role in DNA damage response and cell cycle control in the 
nucleus, and in response to oxidative stress on the Golgi region. However, it is still unclear 
how the localization of Lyn to the nucleus or the Golgi region is regulated.  
   We investigated the mechanism of the distribution of Lyn between the cytoplasm and the 
nucleus in epitheloid HeLa cells and hematopoietic THP-1 cells. Lyn was definitely detected 
in purified nuclei by immunofluorescence and immunoblotting analyses. Nuclear 
accumulation of Lyn was enhanced upon treatment of cells with leptomycin B (LMB), an 
inhibitor of Crm1-mediated nuclear export. Moreover, Lyn mutants lacking the sites for lipid 
modification were highly accumulated in the nucleus upon LMB treatment. Intriguingly, 
inhibition of the kinase activity of Lyn by SU6656, Csk overexpression, or point mutation in 
the ATP-binding site induced an increase in nuclear Lyn levels. These results suggest that 
Lyn being imported into and rapidly exported from the nucleus preferentially accumulates in 
the nucleus by inhibition of the kinase activity and lipid modification. 
   Next, we explored which domains are involved in the Golgi targeting of Lyn. Alanine 
substitution or deletion of the SH3 and SH2 domains of Lyn did not affect the Golgi 
localization of Lyn, suggesting that protein interactions through these domains are not 
required for Lyn targeting to the Golgi region. Although palmitoylation of Lyn is 
indispensable for localization of Lyn to the Golgi region, lipid modifications are not sufficient 
for the Golgi targeting of Lyn. Deletion of the kinase domain of Lyn inhibited its 
colocalization with the Golgi caveolin and trafficking to the plasma membrane. Therefore, 
besides the lipid modification, the kinase domain of Lyn plays a role in the targeting and 
trafficking of Lyn through the Golgi toward the plasma membrane. 
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Introduction 
 
   In multicellular organisms, protein-tyrosine phosphorylation is well known to have a 
pivotal role in the coordination of signal transduction, which is involved in the control of a 
wide range of cellular processes, such as cell adhesion, gene transcription, differentiation, and 
cell proliferation [1]. Although tyrosine phosphorylation is associated with cytoplasmic 
events, it also directly originates in the nucleus, such as DNA damage response [2]. The 
physical separation of the nucleus and the cytoplasm provides an added level of spatial 
regulation of protein activity [3]. Therefore, it is of interest to note that nucleocytoplasmic 
transport of signaling proteins may be tightly regulated for their proper biological functions. 
Recent evidence provides a novel view that not only the plasma membrane and the nucleus 
but also endomembranes, such as the Golgi apparatus and endoplasmic reticulum (ER), may 
serve as a platform of signaling molecules and that distinctive localization of signaling 
molecules are implicated in their specific functions [4,5].  
   Src-family kinases, which belong to a family of nonreceptor-type tyrosine kinases, consist 
of proto-oncogene products and structurally related proteins and include at least eight highly 
homologous proteins: c-Src, Lyn, Fyn, c-Yes, c-Fgr, Hck, Lck, and Blk [6,7]. Src-family 
kinases are known to play crucial roles in regulating cell proliferation, differentiation, 
migration, and cell-shape changes [7]. Overexpression and enhanced activity of Src-family 
kinases found in a large number of human malignancies have been linked to the development 
of cancer and progression to metastases [8,9], and there has recently been a renewed interest 
in Src-family kinases as molecular targets for cancer therapy [10]. 
   Src-family kinases are composed of (i) an NH2-terminal Src homology (SH) 4 domain that 
contains lipid modification sites, (ii) a poorly conserved “unique” domain, (iii) an SH3 
domain, which can bind to specific proline-rich sequences, (iv) an SH2 domain, which can 
bind to specific site of tyrosine phosphorylation, (v) a tyrosine kinase catalytic domain, and 
(vi) a negative regulatory tail for autoinhibition of kinase activity [7,8]. The tyrosine kinase 
activity of Src-family kinases is repressed through creating a distinctive “closed 
conformation” due to the intramolecular bindings of the SH2 domain to the 
tyrosine-phosphorylated tail catalyzed by the Csk-family kinases and of the SH3 domain to 
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the SH2-kinase linker. Src-family kinases can interact with a large number of upstream 
regulators and downstream substrates through protein-protein interactions [7,8]. 
   Lyn, a member of Src-family kinases, is widely expressed in a variety of organs, tissues, 
and cell types, such as epidermoid, hematopoietic, and neural cells, and plays an important 
role in signal transduction at the cytoplasmic face of the plasma membrane [11-19]. Our 
recent studies showed that newly synthesized Lyn localizes to the plasma membrane via the 
Golgi apparatus along the secretory pathway [20]. In addition to myristoylation at its 
N-terminal Gly-2, palmitoylation of Lyn at Cys-3 is critical for its membrane localization and 
trafficking [21-26]. Furthermore, we showed that Lyn phosphorylates annexin II on the Golgi 
apparatus, leading to the translocation of annexin II from the Golgi apparatus to the 
endoplasmic reticulum [25]. Cell fractionation and confocal microscopy demonstrated that 
Lyn is expressed in the nucleus and that nuclear Lyn is activated in cell cycle regulation and 
DNA damage-induced apoptosis [17,27-29]. Although distinct localizations of Lyn are 
critical for its function, little is known as to how the distribution of newly synthesized Lyn to 
the nucleus and the Golgi apparatus is regulated. 
   In this study, we examined the regulation of the distribution of Lyn to the nucleus and the 
Golgi apparatus. We showed that Lyn is rapidly exported from the nucleus through 
Crm1-mediated nuclear export. We further investigated the mechanism underlying the 
nucleocytoplasmic distribution of Lyn and showed that the kinase activity and lipid 
modification of Lyn affect the nucleocytoplasmic distribution of Lyn. We also showed that 
the kinase domain of Lyn is indispensable for the Golgi targeting and subsequent trafficking 
of Lyn. 
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Materials and Methods 
 
Plasmids 
   cDNAs encoding human wild-type p56 Lyn ([30]; provided by T. Yamamoto, The 
University of Tokyo) and its mutants were subcloned into the pcDNA4/TO vector 
(Invitrogen). Lyn(G2A/C3A), which lacks the sites for lipid modification (Gly2→Ala, 
Cys3→Ala), was generated by site-directed mutagenesis using the sense primer 
5'-GAAACTTTCACCGCGGGCGGGAAATATGGCAGCTATAAAATCAAAAGGG-3' and 
the antisense primer 5'-CCCTTTTGATTTTATAGCTGCCATATTTCCCGCCCGCGGTGA 
AAGTTTC-3'. The resulting fragment was confirmed by sequencing. Lyn∆SH4 was 
generated by site-directed mutagenesis using the sense primer 5'-GCTTGAGTGACGATCGA 
GTAGATTTGAAGACTCAACC-3' and the antisense primer 5'-GGTTGAGTCTTCAAAT 
CTACTCGATCGTCACTCAAGC-3' to introduce PvuI restriction site at the boundary 
between the SH4 domain and the unique domain. The Lys→Ala mutation at position 275 in 
the ATP binding site (kinase-dead, K275A) was constructed as described previously [20]. 
Lyn118(G2A/C3A)-GFP, Lyn118-GFP and Lyn244-GFP were constructed by fusion with 
GFP obtained from pEGFP-C1 (CLONTECH Laboratories) as described previously [31]. Rat 
Csk cDNA ([32]; provided by M. Okada and S. Nada, Osaka University) was subcloned into 
the pME18S vector. Human magphinin-α cDNA (provided by M. N. Fukuda, The Burnham 
Institute for Medical Research) was subcloned into the pMH6 vector (Roche) as described 
previously [33]. The Trp-Ala mutation at position 99 [Lyn(W99A)-HA, Lyn118(W99A)-GFP 
and Lyn244(W99A)-GFP] was generated by site-directed mutagenesis using the primers as 
described previously [31]. The Arg-Ala mutation at position 156 [Lyn(R156A)-HA] was 
generated by site-directed mutagenesis using the sense primer 
5'-CTGGAGCTTTCCTTATTGCAGAAAGTGAAACGTTAAAAGGAAGCTTCTC-3' and 
the antisense primer 5'-GAGAAGCTTCCTTTTAACGTTTCACTTTCTGCAATAAGGAAA 
GCTCCAG-3'. LynΔSH3ΔSH2-HA and Lyn(C3S)ΔSH3ΔSH2-HA were generated by 
deleting the sequence of the SH3 and the SH2 domains of Lyn-HA and Lyn(C3S)-HA, 
respectively. LynΔK-HA and LynΔK-GFP were constructed as described previously [20, 24]. 
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Antibodies 
Mouse monoclonal anti-Lyn (H-6; Santa Cruz Biotechnology, and Lyn9; Wako Pure 
Chemical Industries, Osaka), anti-lamin B1 (L-5; Zymed Laboratories), anti-desmoglein 
(clone 62; BD Transduction Laboratories), anti-actin (MAB1501; CHEMICON International), 
anti-HA (F-7; Santa Cruz Biotechnology), rabbit polyclonal anti-phospho-Src-family 
(Src[pY416]; Cell Signaling Technology), anti-Csk (C-20; Santa Cruz Biotechnology), and 
anti-Lyn (H-44; Santa Cruz Biotechnology) were used. Horseradish peroxidase 
(HRP)-conjugated F(ab’)2 fragments of anti-mouse IgG or anti-rabbit IgG were purchased 
from Amersham Biosciences. FITC-conjugated F(ab’)2 fragment of anti-mouse IgG and 
TRITC-conjugated anti-mouse IgG or anti-rabbit IgG were obtained from BioSource 
International and Sigma-Aldrich, respectively. 
 
Cells and transient transfection 
   COS-1 cells and HeLa cells (Japanese Collection of Research Bioresources, Osaka) were 
cultured in Iscove’s modified Dulbecco’s medium (IMDM) containing 5% fetal bovine serum 
(FBS) at 37ºC in a humidified atmosphere of 5% CO2-95% air. The acute monocytic leukemia 
cell line THP-1 cells (provided by A. Iwama, Chiba University) were cultured in IMDM 
containing 5% FBS and 50 µM 2-mercaptethanol. HeLa cells were transiently transfected 
with pcDNA4/TO vector (Invitrogen) encoding wild-type p56 Lyn or Lyn mutants using 
TransIT Transfection reagent (Mirus) or linear polyethylenimine (25 kDa), according to the 
manufacturer’s instructions, as reported previously [17,20,31]. For inhibition of 
Crm1-mediated nuclear export, cells were cultured in the presence or absence of 5 ng/ml 
leptomycin B (LC Laboratories) for 12 h. For inhibition of the kinase activity of Lyn, HeLa 
cells transfected with Lyn or its mutants were cultured for 24 h, and treated with 10 µM 
SU6656 (Calbiochem; [10]) for the last 30min. THP-1 cells were cultured for 12 h in the 
absence or presence of 5 µM SU6656. In co-transfection with Lyn(G2A/C3A) and Csk, HeLa 
cells were transfected with Lyn(G2A/C3A) at 9 h after transfection with Csk and 
subsequently cultured for further 21 h. For inhibition of secretory pathway, COS-1 cells were 
cultured at 19ºC for 2 h. 
 
 - 7 - 
Immunofluorescence 
   Immunofluorescent staining was performed as described [16,17,20,23-26,33-36]. In brief, 
HeLa cells were fixed in phosphate-buffered saline (PBS) containing 4% paraformaldehyde 
for 20 min at room temperature, and permeabilized in PBS containing 0.1% saponin and 3% 
bovine serum albumin. Cells were subsequently reacted with an appropriate primary antibody 
for 1 h, washed with PBS containing 0.1% saponin, stained with FITC- or TRITC-conjugated 
secondary antibody for 1 h, and mounted with Prolong Antifade™ reagent (Molecular 
Probes). For staining of nuclei, cells were treated with 200 µg/ml RNase A and 100 µg/ml 
propidium iodide (PI) for 30 min. THP-1 cells in suspension culture were cytocentrifuged and 
attached to a coverslip after fixation with 4% paraformaldehyde. Permeabilization and 
immunostaining of THP-1 cells were performed as described above. Confocal and Nomarski 
differential-interference-contrast images were obtained using a Fluoview FV500 laser 
scanning microscope with 40 x 1.00 NA oil objective (Olympus, Tokyo). Care was taken to 
ensure that detection sensitivity was kept constant and that there was no breed-through from 
the fluorescein signal into the red channel. One-planar (xy) section slice images with 0.6-µm 
thickness were shown. Orthogonal sections viewing axial directions (xz and yz) were created 
when all Z-series sections at 0.3-0.5 µm intervals were merged. Composite figures were 
prepared using Photoshop 5.0 and Illustrator 9.0 software (Adobe). 
 
Purification of nuclei 
   Cells were washed with D-PBS(-) twice, followed by washing with detergent-free 
hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, and 10 mM KCl). Cells swollen in 
hypotonic buffer for 1 h were homogenized with 10 strokes in a tight-fitting 1-ml Dounce 
homogenizer. After adjusting to 150 mM NaCl, homogenized samples were centrifuged at 
135 x g for 5 min. The resulting pellet was washed with isotonic buffer (150 mM NaCl, 10 
mM HEPES, pH 7.9, 1.5 mM MgCl2, and 10 mM KCl) three times, and lysed in SDS sample 
buffer. All steps were carried out at 4ºC. For immunofluorescence experiments, purified 
nuclei were cytocentrifuged and immunostained as described above. 
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Western blotting and Immunoprecipitation 
   Western blotting was performed as described previously [13,14,19,20,23-26,33-37]. In 
brief, whole cell lysates were prepared in SDS sample buffer at 4ºC, subjected to 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and electrotransferred onto 
polyvinylidene difluoride membranes (Millipore). Immunodetection was performed by 
enhanced chemiluminescence (Amersham Biosciences). Sequential reprobing of membranes 
with a variety of antibodies was performed after the complete removal of primary and 
secondary antibodies from membranes in stripping buffer or inactivation of HRP by 0.1% 
NaN3, according to the manufacturer’s instructions. Results were analyzed using an image 
analyzer LAS-1000plus equipped with Science Lab software (Fujifilm Co., Tokyo). For 
immunoprecipitation, cells were lysed in Triton X-100 lysis buffer (60 mM HEPES, pH 7.4, 
10% glycerol, 1% Triton X-100, 10 mM EDTA, 100 mM NaF, and 10 mM Na3VO4) at 4ºC, 
and the resultant Triton lysates were incubated at 4ºC with protein G-Sepharose beads 
(Amersham Biosciences) precoated with anti-Lyn antibody (Lyn9). The immune complexes 
were analyzed by SDS-PAGE and Western blotting, as described above. 
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Results and Discussions 
 
Section I 
Nuclear localization of Lyn tyrosine kinase mediated 
by inhibition of its kinase activity 
 
Results 
Accumulation of Lyn in the nucleus by leptomycin B 
   Lyn is expressed in a wide variety of tissues, abundantly in hematopoietic cells. To 
scrutinize the distribution of Lyn in hematopoietic cells, we tried to visualize endogenous Lyn 
in human monocytic leukemia THP-1 cells by immunofluorescence. Large amounts of Lyn 
were found at the plasma membrane and the perinuclear region, and small amounts of Lyn 
could be detected in the nucleus (Fig. 1A, upper panels). To examine a role for nuclear export 
in localization of Lyn, we treated THP-1 cells with leptomycin B (LMB), a potent inhibitor of 
Crm1-mediated nuclear export. Treatment with LMB was found to increase the amounts of 
Lyn in the nucleus (Fig. 1A, compare lower panels with upper panels). A similar result was 
seen in human monocytic leukemia U937 cells (data not shown). To further substantiate the 
nuclear localization of Lyn, nuclei were highly purified by elimination of the plasma 
membrane and the perinuclear organelle where Lyn was abundantly present. Purified nuclei 
were confirmed by Nomarski optics and Western blotting with an antibody to the plasma 
membrane protein desmoglein (Fig. 1B,C). Fig. 1B shows that endogenous Lyn was clearly 
detected in purified nuclei by immunofluorescence with anti-Lyn antibody. As a control, no 
staining was observed without the primary antibody (Fig. 1B, left panels). These results 
indicate a small fraction of endogenous Lyn indeed localizes in the nucleus although a 
majority of Lyn localizes to the plasma membrane and the perinuclear region. The nuclear 
accumulation of Lyn by LMB treatment was analyzed by Western blotting using purified 
nuclei prepared from THP-1 cells that were cultured in the absence or presence of LMB. Fig. 
1C shows that two isoforms of endogenous Lyn at 53 kDa and 56 kDa were detected in 
purified nuclei with anti-Lyn antibody, consistent with the result obtained from 
immunofluorescence experiments (Fig. 1A,B). Fig. 1C also shows that upon treatment with 
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LMB, the amounts of endogenous Lyn present in the nucleus were increased approximately 
1.5-fold, while the amounts of the nuclear lamina protein lamin B1 were comparable in each 
nuclear sample. These results suggest that Lyn is accumulated in the nucleus by inhibition of 
Crm1-mediated nuclear export. 
 
Effect of lipid modification of Lyn on its nuclear localization 
   We next examined whether nuclear accumulation of Lyn was detected in HeLa cells as 
well as THP-1 cells, because we recently showed that Lyn expressed in HeLa cells is 
localized to the plasma membrane and the perinuclear region [20]. However, endogenous Lyn 
present in the nucleus of HeLa cells could not be visualized by our immunostaining probably 
due to its low expression. Then, HeLa cells were transiently transfected with human wild-type 
Lyn (Lyn-wt; Fig. 2A) and cultured in the absence or presence of LMB. Like endogenous Lyn 
present in THP-1 cells (Fig. 1A), expressed Lyn in HeLa cells were detected not only at the 
plasma membrane and the perinuclear region but also in the nucleus (Fig. 2B). The amount of 
Lyn present in the nucleus was increased upon treatment with LMB (Fig. 2B). As a control, 
magphinin-α, a trophinin-related cytoplasmic protein [33], was retained in the cytoplasm 
irrespective of LMB treatment (Fig. 2B, right panels). Despite a small increase, accumulation 
of Lyn in the nucleus is enhanced by LMB treatment in HeLa cells, as seen in THP-1 cells. 
   Lyn has sites for N-myristoylation at Gly-2 and palmitoylation at Cys-3 in the SH4 
domain (Fig. 2A), which are indispensable for anchoring to membranes [21,22]. Although 
newly synthesized Src-family kinases are rapidly myristoylated in the cytoplasm [38], not all 
molecules of Src-family kinases contain myristic acid [39]. We hypothesized that Lyn lacking 
sites for lipid modification is likely to localize to the nucleus. Hence, we constructed 
Lyn(G2A/C3A), a Lyn mutant that lacks lipid modification sites by replacing Gly-2 and 
Cys-3 to alanine, and examined its localization in HeLa cells. Unlike Lyn-wt, Lyn(G2A/C3A) 
was not localized to membranes but diffused in the cytoplasm (Fig. 2C, left). As shown in Fig. 
2D, HeLa cells expressing Lyn mutants were classified into two categories: N<C localization, 
expression in the nucleus is lower than that in the cytoplasm; N≥C localization, expression in 
the nucleus is higher than or equal to that in the cytoplasm. Localization of Lyn-wt was 
classified as N<C localization because of small amounts of nuclear Lyn (Fig. 2B,E). 
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Unexpectedly, N≥C localization of Lyn(G2A/C3A) was shown in less than 20% of 
transfected cells, and N<C localization of Lyn(G2A/C3A) was shown in the remaining 80% 
of transfected cells (Fig. 2C,E). This may be explained by the possibility that Lyn(G2A/C3A) 
imported into the nucleus can be rapidly exported to the cytoplasm. We therefore examined 
whether Lyn(G2A/C3A) was exported from the nucleus to the cytoplasm through 
Crm1-mediated nuclear export. HeLa cells expressing Lyn(G2A/C3A) were cultured in the 
absence or presence of LMB. Accumulation of Lyn(G2A/C3A) in the nucleus was enhanced 
by LMB treatment (Fig. 2C), and nuclear accumulation of Lyn(G2A/C3A) in the presence of 
LMB was seen in 80% of transfected cells (Fig. 2E). These results suggest that 
Lyn(G2A/C3A) is imported into the nucleus but is rapidly exported from the nucleus to the 
cytoplasm through the Crm1-mediated nuclear export system. The amount of Lyn(G2A/C3A) 
accumulated in the nucleus by LMB treatment was much larger than that of Lyn-wt, 
indicating that membrane anchoring of Lyn through lipid modification inhibits nuclear 
localization of Lyn. 
 
Role of the Lyn N-terminal region in nuclear localization of Lyn 
   Since previous studies showed that Lyn is cleaved in its N-terminal region by caspase 3 
during induction of apoptosis [40], the N-terminal region of Lyn may be linked to regulation 
of nuclear localization of Lyn. To identify the region of Lyn responsible for 
nucleocytoplasmic trafficking, we constructed Lyn∆SH4 by deleting the SH4 domain, which 
is a mimic of N-terminal cleaved Lyn by caspase 3 (Fig. 3A), and examined its localization in 
HeLa cells. Unlike Lyn-wt and Lyn(G2A/C3A), Lyn∆SH4 was distributed throughout the 
nucleus and the cytoplasm even in the absence of LMB (Fig. 3B,C) and the levels of nuclear 
accumulation of Lyn∆SH4 were larger than those of Lyn(G2A/C3A). These results suggest 
that the N-terminal region of Lyn plays an inhibitory role in nuclear localization of Lyn. 
   To further examine whether the N-terminal region of Lyn played a role in nuclear export 
of Lyn, we constructed Lyn118(G2A/C3A)-GFP, in which the N-terminal region of Lyn was 
fused with GFP (Fig. 3A), and examined its subcellular localization. Surprisingly, most of 
Lyn118(G2A/C3A)-GFP was localized to the nucleus rather than the cytoplasm (Fig. 3D,E), 
suggesting that the N-terminal region of Lyn itself is not sufficient for export of Lyn from the 
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nucleus. As a control, Lyn118-GFP, which contains lipid modification sites, showed 
membrane-anchored localization (Fig. 3D,E). Taken together with the finding that mutation 
of lipid modification sites in Lyn does not fully induce nuclear accumulation of Lyn (Fig. 2C), 
these results suggest that besides the N-terminal region, the other domain(s) of Lyn is 
involved in the nucleocytoplasmic trafficking of Lyn.  
 
Effect of the kinase activity of Lyn on its nuclear export 
   Since Lyn118(G2A/C3A)-GFP, which lacks the kinase domain, was highly accumulated 
in the nucleus (Fig. 3D,E), we examined whether the kinase activity of Lyn was involved in 
the nucleocytoplasmic trafficking of Lyn. We constructed a kinase-dead (KD) Lyn mutant, 
Lyn(G2A/C3A)-KD, by replacing Lys-275 to alanine in the ATP-binding site (Fig. 3A). 
Western blotting analysis with anti-phospho-Src-family antibody confirmed that 
Lyn(G2A/C3A)-KD was deficient in tyrosine kinase activity (Fig. 4A). To examine the 
localization of Lyn(G2A/C3A)-KD, HeLa cells were transfected with Lyn(G2A/C3A)-KD. 
Unlike Lyn(G2A/C3A), Lyn(G2A/C3A)-KD was abundantly localized to the nucleus (Fig. 
4B,C), suggesting that the kinase activity of Lyn plays a role in the nucleocytoplasmic 
trafficking of Lyn. To examine whether the kinase activity of Lyn affected its nuclear export, 
HeLa cells expressing Lyn(G2A/C3A)-KD were cultured in the absence or presence of LMB. 
Similar to Lyn(G2A/C3A) (Fig. 2C,E), Lyn(G2A/C3A)-KD was considerably accumulated in 
the nucleus by treatment with LMB (Fig. 4D,E), indicating that Lyn(G2A/C3A)-KD is 
exported from the nucleus through Crm1-mediated nuclear export. These results suggest that 
the level of nuclear Lyn(G2A/C3A) is increased by inhibition of its kinase activity. 
 
Nuclear localization of Lyn induced by Src inhibition 
   Next, we examined the effect of Src inhibition on the localization of Lyn(G2A/C3A), 
because Lyn(G2A/C3A)-KD was abundantly localized to the nucleus. Given that the catalytic 
activity of Src-family kinases can be inhibited by creating a “closed conformation” through 
Csk tyrosine kinase-mediated phosphorylation of their COOH-terminal tyrosine residue [4], 
HeLa cells were co-transfected with Lyn(G2A/C3A) and Csk. More than 70% of cells 
expressing Lyn(G2A/C3A) were co-expressed with Csk, and most of Csk were distributed in 
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the cytoplasm. Fig. 5A,B shows that accumulation of Lyn(G2A/C3A) in the nucleus was 
markedly enhanced by Csk overexpression. Western blotting analysis confirmed that the 
kinase activity of Lyn(G2A/C3A) was decreased by Csk overexpression (Fig. 5C). In contrast 
to Lyn(G2A/C3A), Lyn(G2A/C3A)-GFP, which is devoid of the C-terminal inhibitory 
tyrosine residue, was unaffected in its localization and kinase activity by Csk co-expression 
(Supplementary Fig. S1). Furthermore, we tested whether SU6656, a potent Src inhibitor, 
increased nuclear localization of Lyn(G2A/C3A). Similar to the result of Csk overexpression, 
treatment of HeLa cells expressing Lyn(G2A/C3A) with SU6656 resulted in an increase in 
nuclear accumulation of Lyn(G2A/C3A) (Fig. 5D,E), accompanied by inhibition of 
Lyn(G2A/C3A) kinase activity (Fig. 5F). These results suggest that inhibition of the kinase 
activity of Lyn increases the amounts of nuclear Lyn. 
   To further ascertain the involvement of the kinase activity of Lyn in its nuclear 
localization, we examined whether the amount of Lyn-wt present in the nucleus was increased 
by inhibition of its kinase activity although the nuclear accumulation of Lyn-wt is much less 
than that of Lyn(G2A/C3A). The effect of SU6656 treatment on nuclear localization of 
Lyn-wt was analyzed by Western blotting using purified nuclei from HeLa cells that were 
transfected with Lyn-wt and cultured in the absence or presence of SU6656. As shown in Fig. 
5G, the amount of Lyn-wt present in the nucleus was increased upon treatment with SU6656. 
Taken together, these results suggest that the level of kinase activity of Lyn is an important 
factor in the distribution of Lyn in the nucleus and the cytoplasm. 
 
Nuclear localization of endogenous Lyn induced by Src inhibition in THP-1 cells 
   To examine whether the level of endogenous Lyn (p53/p56) present in the nucleus was 
increased by inhibition of its kinase activity, we treated THP-1 cells with SU6656. Western 
blotting analysis showed that treatment with SU6656 significantly increased the amounts of 
nuclear Lyn (Fig. 6A). Since we could not detect the kinase activity of endogenous Lyn by 
Western blotting with anti-Src[pY416] antibody possibly due to its low expression, we then 
tried to immunoprecipitate endogenous Lyn present in the nucleus. Although the recovery of 
Lyn(p53) was much lower than that of Lyn(p56), immunoprecipitation analysis confirmed 
that treatment of THP-1 cells with SU6656 decreased the kinase activity of endogenous Lyn 
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(Fig. 6B). These results suggest that nuclear accumulation of endogenous Lyn is increased by 
inhibition of its kinase activity. 
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Discussion 
   In the present study, we show that Lyn, known to anchor to membranes, is distributed 
between the cytoplasm and the nucleus. Lyn is rapidly exported from the nucleus through 
Crm1-mediated nuclear export. Besides lipid modification of Lyn, the level of its kinase 
activity contributes to the nucleocytoplasmic distribution of Lyn. Indeed, inhibition of the 
kinase activity of Lyn increases the amounts of nuclear Lyn. 
   Although it is known that Lyn localizes to the cytoplasmic face of the plasma membrane 
and plays a role in signal transduction as a signaling molecule, Lyn is also found in the 
nucleus in hematopoietic cells and fibroblastic cells [17,27-29]. Here, we demonstrate the 
regulation of localization of Lyn in the nucleus: (i) Lyn is obviously detected in purified 
nuclei from HeLa and THP-1 cells (Figs. 1A, 1C, 2B, 5G, and 6), (ii) nuclear accumulation of 
Lyn is enhanced by LMB-mediated inhibition of nuclear export (Figs. 1A,C and 2B), (iii) 
inhibition of the kinase activity of Lyn increases the amount of nuclear Lyn (Figs. 4, 5 and 6). 
   How can Lyn localize to the nucleus? The N-terminal region of newly synthesized Lyn is 
covalently myristoylated at Gly-2 and subsequently palmitoylated at Cys-3, and these 
modifications are needed for membrane association [21,22]. We initially hypothesized that 
deletion of the sites for lipid modification of Lyn would enhance nuclear accumulation of Lyn. 
Although double mutation of Gly-2 and Cys-3 to Ala inhibits membrane anchoring of Lyn 
and increases the amount of nuclear Lyn to some extent, most of Lyn(G2A/C3A) are still 
found in the cytoplasm (Fig. 2C,E). However, it should be noted that LMB treatment greatly 
induces nuclear accumulation of Lyn(G2A/C3A) (Fig. 2C,E), meaning that non-myristoylated 
Lyn may be easily distributed in the nucleus but rapidly exported to the cytoplasm. Previous 
report showed that about 16% of newly synthesized Src are not myristoylated and fail to 
associate with membranes [39]. However, it is difficult to determine whether nuclear Lyn is 
myristoylated, because a fraction of Lyn present in the nucleus is hardly solubilized by 
detergents. 
   Although we can assume that lipid modification of Lyn has an inhibitory role in 
distribution of Lyn to the nucleus, most of Lyn(G2A/C3A) indeed localize in the cytoplasm 
rather than accumulate in the nucleus. It is expected that besides the SH4 domain of Lyn 
containing the lipid modification sites, another domain(s) of Lyn may contribute to the 
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regulation of localization of Lyn to the nucleus. Our findings indicate that the kinase activity 
of Lyn is involved in the nucleocytoplasmic distribution of Lyn. The amount of 
Lyn(G2A/C3A) present in the nucleus is increased by inhibition of its kinase activity (Figs. 4 
and 5). There is no difference in LMB-induced nuclear accumulation between 
Lyn(G2A/C3A) and Lyn(G2A/C3A)-KD (Figs. 2E and 4E), indicating that inhibition of the 
kinase activity of Lyn does not influence the nuclear export. Because of active nuclear export, 
40~50% of cells still exhibit cytoplasmic localization of Lyn upon inhibition of the kinase 
activity (Figs. 4C and 5B,E). These results raise the possibility that kinase-active Lyn cannot 
easily enter the nucleus. Recent evidence provides a view that the kinase activity of the 
non-receptor-type protein-tyrosine kinases Abl and focal adhesion kinase (FAK) has an 
inhibitory role in their localization to the nucleus. The kinase activity of Bcr-Abl tyrosine 
kinase mediates its cytoplasmic retention [41]. The nuclear localization of FAK is enhanced 
upon treatment with the protein kinase inhibitor staurosporine [42]. Taken together, we think 
that like Abl and FAK, low levels of nuclear Lyn may be explained by cytoplasmic retention 
of active Lyn.  
   Since nuclear pore complexes restrain free passage of proteins larger than approximately 
40 kDa [43], the translocation of Lyn into and out of the nucleus must be an active process 
involving specific nuclear localization and export signals. The finding of nuclear 
accumulation of Lyn by LMB treatment reveals that Lyn is exported from the nucleus through 
Crm1-mediated nuclear export. A nuclear export signal (NES) is defined as a short amino 
acid sequence of regularly spaced hydrophobic residues, of which leucine is statistically the 
most abundant [44,45], but Lyn has no consensus NES in its primary structure. Therefore, it is 
possible that Lyn associates indirectly with Crm1 through an NES-containing adaptor. 
Previously, it is reported that Syk, a non-receptor-type tyrosine kinase, is imported into the 
nucleus and the C-terminus of the SH2-kinase linker region (356EVYLDRSLLTL366) is critical 
for its nuclear translocation [46]. A similar hydrophobic region is found at the beginning of 
the catalytic domain of Lyn (the sequence, 247IKLVKRL253). The alanine substitutions of 
hydrophobic amino acids (247IKLVKRL253) in Lyn(G2A/C3A) blocked nuclear localization of 
Lyn(G2A/C3A) (data not shown). However, this mutation also resulted in the inactivation of 
the Lyn mutant (data not shown). Given that the SH2-kinase linker region is known to play an 
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important role in conformational regulation of Src-family kinases [47], it is likely that this 
mutation adversely affects the conformation of Lyn. At the moment, we do not know whether 
the SH2-kinase linker region in Lyn plays a role in its nuclear localization. 
   Since the control of nucleocytoplasmic transport contributes to the spatiotemporal control 
of cellular activities that are important for cell fate [48], it is expected that nucleocytoplasmic 
transport of Lyn may be regulated spatially and temporally to ensure a proper biological 
response to extracellular signals. During induction of apoptosis in B cells, the N-terminal 
region of Lyn is cleaved by caspases and the cleaved Lyn, which redistributes in the 
cytoplasm, acts as a negative regulator of apoptosis [40,49]. In our experiments, Lyn∆SH4, a 
mimic of the cleaved Lyn, is distributed not only in the cytoplasm but also abundantly in the 
nucleus (Fig. 3B,C), raising the possibility that the cleaved Lyn acts as a signaling molecule 
in the nucleus in response to apoptotic stimuli. Nuclear Lyn is known to play a role in the 
apoptotic response to DNA damage but the cleavage of N-terminal region of Lyn is not 
observed [27-29]. Taken together, the intact form of Lyn present in the nucleus has a role in 
DNA damage response. 
   Nuclear Lyn plays a role in DNA damage-induced apoptosis through association with 
various signaling molecules such as GADD34, Cdc2, SAPK, etc. [29,50,51]. Recent evidence 
indicates a role of Lyn in cell cycle control. Abl and Src kinases, including Lyn, 
phosphorylate the Cdk inhibitor p27, resulting in degradation of p27 and cell cycle 
progression [51-54]. Moreover, deregulation of this process is associated with poor prognosis 
in breast cancer [54]. Thus, nuclear localization of Lyn and its kinase activity should be 
properly regulated for cell cycle control and DNA damage-induced apoptosis. Our findings 
that Lyn cannot easily accumulate in the nucleus provide an insight into spatial and temporal 
regulation of Lyn in various cellular activities. As we showed here that the level of nuclear 
Lyn is elevated by inhibition of the kinase activity, it is presumable that Lyn would be 
activated in the nucleus for cell cycle regulation and DNA damage response by interacting 
with other signaling molecules upstream or downstream of nuclear Lyn. 
   On the basis of these results, we demonstrate the regulation of nucleocytoplasmic 
distribution of Lyn through import into and rapid export from the nucleus and show the 
importance of inhibition of the kinase activity and lipid modification in nuclear accumulation 
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of Lyn. Since low levels of nuclear Lyn detected in intact cells can be explained by sustained 
Crm1-mediated nuclear export and cytoplasmic retention of Lyn, it is suggested that Lyn may 
interact with a nucleocytoplasmic transport carrier or an adaptor. Further exploration of a 
relevant binding protein to Lyn will help us to understand the spatiotemporal regulation of 
nuclear Lyn function. 
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Figure 1. Accumulation of endogenous Lyn in the nucleus upon treatment with leptomycin B.
(A and B) Endogenous Lyn was detected with anti-Lyn antibody followed by FITC-conjugated secondary 
antibody (green). THP-1 cells were cultured for 12 h in the absence (control) or presence (+ LMB) of 5 ng/ml 
leptomycin B (LMB) (A). Purified nuclei from THP-1 cells were stained with anti-Lyn antibody (secondary 
antibody alone, left panel). Purified nuclei were confirmed by Nomarski optics (B). DNA was stained with 
propidium iodide (PI) (red). The areas of nuclei were marked by dashed line. Scale bars, 10 µm. (C) Whole 
cells and purified nuclei from THP-1 cells cultured for 12 h in the absence (-) or presence (+) of 5 ng/ml 
LMB were solubilized and analyzed by Western blotting with anti-Lyn antibody. Two forms of endogenous 
Lyn at 53 kDa and 56 kDa are the translation products of alternatively spliced transcripts. Purified nuclei 
were confirmed by using antibodies to the plasma membrane protein desmoglein and the nuclear lamina 
protein lamin B1. Desmoglein was not detected in the purified nuclear samples. Molecular size markers in 
kDa are indicated on the left. The amounts of nuclear Lyn were quantitated by measuring signal intensities 
detected with anti-Lyn antibody and normalized to the levels of lamin B1 present in purified nuclei and those 
of Lyn in whole cells. Results are expressed relative to the amount of Lyn in control cells. Data represent 
means±SD from four independent experiments. An asterisk indicates the significant difference (*P<0.05) 
calculated by Student's t-test.
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Figure 2. Effect of lipid modification of Lyn on its nuclear accumulation.
(A) A schematic representation of wild-type Lyn (Lyn-wt) is shown with the Src homology (SH) domains, the 
unique region, the tyrosine kinase domain (Y, a tyrosine residue for autophosphorylation), and the C-terminal 
negative regulatory tyrosine residue (Y). Two lipid modification sites are indicated in the amino acid 
sequence of the SH4 domain. Gly-2 and Cys-3 are the sites attached with myristic acid and palmitic acid, 
respectively. (B) HeLa cells transfected with Lyn were cultured for 36 h in the absence (control) or presence 
(+ LMB) of 5 ng/ml LMB during the last 12 h. Cells were stained with anti-Lyn antibody and PI. The areas of 
nuclei were marked by dashed line. As a control, transfected magphinin-± was observed in the cytoplasm 
irrespective of treatment with LMB (right panels). Scale bars, 20 µm. (C) HeLa cells transfected with 
Lyn(G2A/C3A) were cultured for 36 h in the absence or presence of 5 ng/ml LMB during the last 12 h and 
stained with anti-Lyn antibody and PI. Nuclear and cytoplasmic staining of Lyn(G2A/C3A) are indicated by 
arrows and arrowheads, respectively. Scale bars, 20 µm. (D) HeLa cells expressing Lyn mutants were 
classified into two categories. N<C, protein expression in the nucleus is lower than that in the cytoplasm; 
N≥C, protein expression in the nucleus is greater than or equal to that in the cytoplasm. Note that “N≥C 
localization” does not include the nuclear localization of Lyn-wt, because amounts of nuclear Lyn-wt were 
smaller than those of cytoplasmic Lyn-wt. Scale bars, 20 µm. (E) N≥C localization of Lyn(G2A/C3A) in the 
absence or presence of LMB was quantitated according to the classification as described in (D). Results (%) 
represent means ± SD from at least three independent experiments. Asterisks indicate significant differences 
(***P<0.001) calculated by Student's t-test.
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Figure 3-2
Figure 3. Role of the N-terminal region of Lyn in its nuclear localization.
(A) Schematic representations of the constructs used in this study are shown. (G2A/C3A), alanine 
substitution at Gly-2 and Cys-3; KD, kinase-dead mutation; ∆SH4, deletion of the SH4 domain; Lyn118, the 
N-terminal Lyn sequence (1-118 amino acid residues). (B and D) HeLa cells transfected with the indicated 
constructs were cultured for 24 h, and localization of each protein was detected with anti-Lyn or anti-HA 
antibody, and GFP fluorescence. Nuclei were stained with PI. Arrows indicate cells exhibiting the nuclear 
localization of Lyn mutants. Scale bars, 20 µm. (C) N≥C localization of each Lyn mutant shown in (B) was 
quantitated. Results (%) represent means ± SD from at least three independent experiments. The difference 
between Lyn(G2A/C3A) and Lyn∆SH4 was calculated by Student's t-test. Asterisks indicate the significant 
difference (***P<0.001). (E) N≥C localization of Lyn118 and Lyn118(G2A/C3A) shown in (D) was 
quantitated from a representative experiment. 
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Figure 4-1
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Figure 4-2
Figure 4. Effect of the kinase activity of Lyn on its nuclear localization. 
(A) Whole cell lysates from HeLa cells transfected with nothing, Lyn(G2A/C3A), or Lyn(G2A/C3A)-KD 
were analyzed by Western blotting with the indicated antibodies. Autophosphorylation of each Lyn mutant 
was detected with anti-Src[pY416] antibody. (B) HeLa cells transfected with Lyn(G2A/C3A) or 
Lyn(G2A/C3A)-KD were cultured for 24 h and stained with anti-Lyn antibody. Arrows indicate cells 
exhibiting the nuclear localization of Lyn mutants. Scale bars, 20 µm. (C) N≥C localization of each mutant as 
shown in (B) was quantitated. Results (%) represent means ± SD from at least three independent experiments. 
Asterisks indicate the significant difference (**P<0.01) calculated by Student's t-test. (D) HeLa cells 
transfected with Lyn(G2A/C3A)-KD were cultured for 36 h in the absence or presence of 5 ng/ml LMB 
during the last 12 h and stained with anti-Lyn antibody. Arrows indicate cells exhibiting the nuclear 
localization of Lyn(G2A/C3A)-KD. Scale bars, 20 µm. (E) N≥C localization of Lyn(G2A/C3A)-KD in the 
absence or presence of LMB. Results (%) represent means ± SD from at least three independent experiments. 
Asterisks indicate the significant difference (***P<0.001) calculated by Student's t-test.
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Figure 5-1
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Figure 5. Nuclear localization of Lyn induced by Src inhibition.
(A) HeLa cells transfected with Lyn(G2A/C3A) or Lyn(G2A/C3A) plus Csk were cultured for 30 h and 
stained with anti-Lyn and anti-Csk antibodies. Arrows indicate cells exhibiting the nuclear localization of 
Lyn(G2A/C3A). Scale bars, 20 µm. (B) N≥C localization of Lyn(G2A/C3A) as shown in (A) was quantitated. 
Results (%) represent means ± SD from at least three independent experiments. Asterisks indicate the 
significant difference (***P<0.001) calculated by Student's t-test. (C) Autophosphorylation of 
Lyn(G2A/C3A) in the absence or presence of overexpressed Csk in HeLa cells was analyzed by Western 
blotting with the indicated antibodies. Lyn kinase activity was quantitated by measuring signal intensities 
detected with anti-Src[pY416] antibody and normalized to the corresponding signal intensities detected with 
anti-Lyn antibody. Results are expressed relative to the kinase activity of Lyn in control cells. Data represent 
means ± SD from three independent experiments. Asterisks indicate the significant difference (***P<0.001) 
calculated by Student's t-test. (D-F) (D) HeLa cells transfected with Lyn(G2A/C3A) were cultured for 24 h in 
the absence (control) or presence (+ SU6656) of 10 µM SU6656 during the last 30 min. Localization of 
Lyn(G2A/C3A) was examined by staining with anti-Lyn antibody followed by TRITC-conjugated secondary 
antibody. Arrows indicate cells exhibiting the nuclear localization of Lyn(G2AC3A). Scale bars, 20 µm. (E) 
N≥C localization of Lyn(G2A/C3A) as shown in (D) was quantitated. Results (%) represent means ± SD from 
at least three independent experiments. Asterisks indicate the significant difference (***P<0.001) calculated 
by Student's t-test. (F) Autophosphorylation of Lyn(G2A/C3A) in the absence or presence of SU6656 in 
HeLa cells was analyzed by Western blotting with the indicated antibodies. Lyn kinase activity was 
quantitated as described in (C), and results are expressed relative to the kinase activity of Lyn in control cells. 
Data represent means ± SD from three independent experiments. Asterisks indicate the significant difference 
(***P<0.001) calculated by Student's t-test. (G) HeLa cells transfected with Lyn-wt were cultured for 24 h in 
the absence or presence of 10 µM SU6656 during the last 30 min. Whole cells and purified nuclei were 
analyzed by Western blotting with anti-Lyn antibody. Purified nuclei were confirmed as described in Fig. 1C. 
Molecular size markers in kDa are indicated on the left. The amounts of nuclear Lyn were quantitated as 
described in Fig. 1C. Results represent means ± SD from three independent experiments. Asterisks indicate 
the significant difference (***P<0.001) calculated by Student's t-test.
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Figure 6
Figure 6. Nuclear localization of endogenous Lyn induced by Src inhibition in THP-1 cells.
(A) THP-1 cells were cultured for 12 h in the absence or presence of 5 µM SU6656. (A) Whole cells and 
purified nuclei were analyzed by Western blotting with anti-Lyn antibody. Purified nuclei were confirmed as 
described in Fig. 1C. Molecular size markers in kDa are shown on the left. The amounts of endogenous Lyn 
(p53/56 Lyn) were quantitated as described in Fig. 1C. Results represent means ± SD from three independent 
experiments. Asterisks indicate the significant difference (*P<0.05) calculated by Student's t-test. (B) Whole 
THP-1 cells and purified THP-1 nuclei were solubilized in Triton X-100 lysis buffer. Lyn immunoprecipitates 
from Triton X-100 lysates were analyzed by Western blotting with anti-Src[pY416] and anti-Lyn antibodies. 
The recovery of Lyn(p53) was much lower than that of Lyn(p56). Molecular size markers in kDa are shown 
on the left.
0
0.5
1.0
1.5
2.0
Co
nt
ro
l
+ 
SU
66
56R
el
at
iv
e 
am
ou
nt
s 
of
 n
uc
le
ar
 L
yn
*
Lyn(G2A/C3A)-GFP Csk Merge
+ 
Cs
k
Co
nt
ro
l
+ 
Cs
k
Co
nt
ro
l
(%)
%
 c
el
ls
 e
xh
ib
iti
ng
 
N≥
C 
lo
ca
liz
at
io
n 
of
 L
yn
0
20
40
60
80
45
200
116
97
66
Lyn(G2A/C3A)-GFP
Csk +
++
Anti-Csk
Anti-Src[pY416]
Anti-Lyn
(kDa)
A
CB
- 31 - 
Supplementary figure S1. Coexpression of Csk with Lyn(G2A/C3A)-GFP, which lacks the C-
terminal inhibitory tyrosine residue.
(A) HeLa cells transfected with Lyn(G2A/C3A)-GFP or Lyn(G2A/C3A)-GFP plus Csk were cultured for 30 h 
and stained with anti-Csk antibody. Scale bars, 20 µm. (B) N≥C localization of Lyn(G2A/C3A)-GFP as 
shown in (A) was quantitated according to the classification as described in Fig. 2D. (C) Autophosphorylation 
of Lyn(G2A/C3A)-GFP in the absence or presence of overexpressed Csk in HeLa cells was analyzed by 
Western blotting with the indicated antibodies. Molecular size markers in kDa are indicated on the right.
Supplementary Figure S1
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Section II 
Role of the kinase domain of Lyn in its localization 
to the Golgi apparatus 
 
Results 
Requirement of the SH4 domain, but not the SH3 and SH2 domains, for the targeting of 
Lyn to the Golgi region 
   We previously reported that newly synthesized Lyn is targeted to the Golgi region and 
then transported to the plasma membrane along the secretory pathway [20]. To examine 
whether the SH3 and SH2 domains of Lyn are involved in the Golgi localization of Lyn, we 
created three Lyn mutants, Lyn(W99A)-HA, Lyn(R156A)-HA and Lyn(W99A/R156A)-HA, 
of which Trp99 in the SH3 domain and/or Arg156 in the SH2 domain was mutated to alanine 
to abolish the binding activity of each domain (Fig. 7A) [55-61]. Similar to Lyn-HA, all of 
alanine-substitution mutants were colocalized with Golgi caveolin (Fig. 7B). These results 
suggest that Lyn localizes to the Golgi region in a manner independent of the binding activity 
of the SH3 and SH2 domains. To further examine the contribution of the SH3 and SH2 
domains to the Golgi localization of Lyn, we constructed LynΔSH3ΔSH2-HA, which lacks 
both the SH3 and SH2 domains. Fig. 7C shows that LynΔSH3ΔSH2-HA was localized to the 
Golgi region, suggesting that the SH3 and SH2 domains are not required for the Golgi 
targeting of Lyn. Since we previously showed that palmitoylation at the SH4 domain of Lyn 
is important for its Golgi localization [23,24], we then constructed Lyn(C3S)ΔSH3ΔSH2-HA, 
a non-palmitoylated form of LynΔSH3ΔSH2-HA. Subcellular localization of 
Lyn(C3S)ΔSH3ΔSH2-HA was compared with that of LynΔSH3ΔSH2-HA. Unlike 
LynΔSH3ΔSH2-HA, Lyn(C3S)ΔSH3ΔSH2-HA showed endosomal localization (Fig. 7C, 
lower panel; [23,24]), indicating that palmitoylation of Lyn is required for the Golgi targeting. 
 
Requirement of the kinase domain of Lyn for its Golgi targeting 
   We next examined whether the kinase domain of Lyn is required for the Golgi 
localization of Lyn because all of Lyn mutants used in Fig.7 contain the kinase domain. We 
therefore created Lyn(SH4-Unique)-GFP and examined its localization. 
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Lyn(SH4-Unique)-GFP was localized to the plasma membrane, but not the Golgi region, 
whereas Lyn-GFP was localized to the Golgi region (Fig. 8A) and in particular colocalized 
with Golgi caveolin (data not shown). To examine whether Lyn(SH4-Unique)-GFP rapidly 
pass through the Golgi region, we took advantage of the property of reduced temperature 
(19ºC) to specifically block TGN membrane vesicle exit [62,63]. As shown in Fig. 8B, 
incubation at 19ºC did not induce accumulation of Lyn(SH4-Unique)-GFP to the Golgi region, 
indicating that Lyn(SH4-Unique)-GFP is not targeted to the Golgi region. In contrast, 
Lyn-GFP was accumulated at the Golgi region after incubation at 19ºC (Fig. 8B). Therefore, 
besides lipid modification, the kinase domain of Lyn is required for its targeting to the Golgi 
region.  
 
Requirement of the kinase domain for Lyn trafficking through the Golgi 
   We previously reported that a kinase domain-deleted Lyn mutant is accumulated in the 
Golgi region because the SH3 and SH2 domains are fully released from steric hindrance of 
the kinase domain [20,24,64]. We examined Golgi localization of two GFP-fused kinase 
domain-deleted Lyn mutants, Lyn118-GFP containing the SH3 domain and Lyn244-GFP 
containing the SH3 and SH2 domains, and found that both mutants were localized at the 
Golgi region and the abolishment of the binding activity of the SH3 domain decreased Golgi 
accumulation (Fig. 9A). We next examined the requirement of the kinase domain for Lyn 
trafficking through the Golgi toward the plasma membrane. COS-1 cells expressing Lyn-GFP 
or Lyn244-GFP were treated with cycloheximide (CHX), an inhibitor of protein synthesis, 
and examined whether each mutant is eliminated from the Golgi region upon treatment with 
CHX. As shown in Fig. 9B, treatment with CHX emptied Lyn-GFP from the Golgi region, 
which was accompanied by elimination of Golgi caveolin (Fig. 9B, insets), whereas 
incubation at 19ºC inhibited the elimination of Lyn-GFP from the Golgi region. However, 
Golgi localization of Lyn244-GFP was immobilized upon treatment with CHX and incubation 
at 19ºC (Fig. 3B, lower panels). These results suggest that the kinase domain is required for 
not only the Golgi targeting but also the trafficking of Lyn through the Golgi toward the 
plasma membrane. 
   To explain the difference between intact Lyn and kinase domain-deleted Lyn mutants, 
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COS-1 cells were cotransfected with Lyn-HA and LynΔK-GFP, and examined their Golgi 
localization. As a result, Lyn-HA and LynΔK-GFP showed incomplete colocalization at the 
Golgi region (Fig. 9C). A similar result was seen when cells were cotransfected with 
Lyn-GFP and LynΔK-HA (data not shown). These results suggest that the Golgi localization 
of LynΔK is not identical to that of intact Lyn, implying that the difference in trafficking of 
between these proteins may be due to their subtle difference in localization within the Golgi 
region. 
 
Colocalization of Lyn, but not LynΔK, with the Golgi caveolin 
   Since the trafficking of Lyn from the Golgi region to the plasma membrane is similar to 
that of caveolin, we next examined the colocalization of Lyn and LynΔK with the Golgi 
caveolin in cross sections of the confocal images. As reported earlier, Lyn-HA was 
colocalized with caveolin at the Golgi region (Fig. 10A; [20]). However, LynΔK-HA was 
minimally colocalized with the Golgi caveolin (Fig. 10B). These results suggest that the 
kinase domain is required for the colocalization of Lyn with the Golgi pool of caveolin, which 
may be important for the Lyn trafficking toward the plasma membrane. 
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Discussion 
   In the present study, we demonstrate that the kinase domain of Lyn plays an indispensable 
role in Lyn trafficking through the Golgi toward the plasma membrane. Although both 
myristoylation and palmitoylation at the N-terminus of Lyn are required for the localization of 
Lyn at the Golgi region, these lipid modifications are not sufficient for the Golgi targeting of 
Lyn. Besides the lipid modification, the kinase domain of Lyn is required for the targeting of 
Lyn to the Golgi pool of caveolin. 
   Our cross sections of the confocal images show that intact Lyn, but not kinase 
domain-deleted Lyn, colocalizes with the Golgi caveolin (Fig. 10). Caveolin is involved in 
exocytic transport and caveolin-containing endosomes are implicated as sites for the sorting 
of caveolin away from the Golgi-bound cargos [65-67]. It is therefore likely that the 
localization of Lyn at the Golgi pool of caveolin is an essential process for exocytic transport 
of Lyn. Previously, caveolin was reported to directly interact with Gα subunits through the 
caveolin binding motif (190FTFKDLHFKMF200) [68,69]. A similar sequience was proposed in 
the kinase domain of Lyn (417FGCFTIKSDVWSFGILLY434) [69]. Despite alanine 
substitutions of large hydrophobic amino acids (417FGCFTIKSDVWSFGILLY434) in Lyn, the 
Lyn mutant is capable of colocalization with caveolin at the Golgi region (data not shown). 
From the crystal structures of c-Src and Hck [47,70,71], the amino acid sequence, which is 
hypothesized as a caveolin binding motif of SFKs, is buried inside the molecule, suggesting 
that Lyn is unlikely to interact with caveolin through the proposed binding motif. In addition, 
we detected the localization of Lyn at the Golgi region in human monocytic leukemia THP-1 
cells [72], in which caveolin is not expressed, meaning that the Golgi targeting of Lyn is 
independent of caveolin expression. Taken together, an interaction through the kinase domain 
of Lyn with other molecules may be important for the Golgi targeting and subsequent 
exocytic trafficking of Lyn. 
   Although the SH3 and SH2 domains are considered to contribute to the localization of 
SFKs [6,7,73], these protein binding domains are not required for the targeting of Lyn to the 
Golgi region (Fig. 7). However, protein-protein interactions through the SH3 and SH2 
domains of Lyn are involved in the retaining at the Golgi region when these domains are 
highly available. Indeed, we show that kinase domain-deleted Lyn mutants, of which the SH3 
 - 36 - 
and SH2 domains are fully released from steric hindrance of the kinase domain, are 
immobilized on the Golgi region (Fig. 9A and B). We recently showed that Lyn has a role as 
a signaling molecule on the Golgi [25], suggesting that the SH3 and SH2 domains of Lyn 
would contribute to the Golgi immobilization of Lyn once Lyn is activated on the Golgi 
region. 
   In conclusion, we show that the kinase domain is important for not only catalytic activity 
but also the trafficking of Lyn through the Golgi toward the plasma membrane. Since 
N-terminal lipid modifications of SFKs are considered to determine the differential trafficking 
of each isoform [22,26,74], the lipid modification sites and the kinase domain concertedly 
contribute to the localization of Lyn to the Golgi region. Further exploration of a relevant 
binding protein to Lyn will help us to understand a key role for targeting and trafficking of 
Lyn to the Golgi region besides the plasma membrane.  
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Figure 7-2
Figure 7. Requirement of the SH4 domain, but not the SH3 and SH2 domains, for the 
targeting of Lyn to the Golgi region
(A) Schematic representations of Lyn and its HA-tagged mutants are shown with the Src homology (SH) 
domains, the unique region, the tyrosine kinase domain, the C-terminal negative regulatory tyrosine (Y), and 
the HA-epitope tag. (B) COS-1 cells transfected with HA-tagged mutants were cultured for 18 h, and doubly 
stained with anti-HA (red) and anti-caveolin (green) antibodies. (C) COS-1 cells transfected with 
Lyn∆SH3∆SH2-HA and Lyn(C3S)∆SH3∆SH2-HA (nonpalmitoylated mutant) were cultured for 18 h and 
stained with anti-HA antibody. Arrows and arrowheads indicate the Golgi localization and endosomal 
localization, respectively. Scale bars, 20 µm.
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Figure 8
Figure 8. Requirement of the kinase domain of Lyn for its Golgi targeting
(A) Schematic representations of Lyn-GFP and Lyn(SH4-Unique)-GFP. COS-1 cells transfected with each 
Lyn mutant were cultured for 18 h. (B) COS-1 cells transfected with Lyn-GFP or Lyn(SH4-Unique)-GFP 
were cultured for 18 h at 37ºC (Control) or 19ºC during the last 3 h. Arrows indicate Golgi localization of Lyn 
mutants. Scale bars, 20 µm.
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B
A
Ly
n2
44
-G
FP
Ly
n-
G
FP
CHX(+)Control CHX(+),19ºC
CHX(+),19ºCCHX(+)Control
0
20
40
60
80
19
ºC
CHX: ++
Pe
riN
 lo
ca
liz
at
io
n
0
20
40
60
80
19
ºC
Pe
riN
 lo
ca
liz
at
io
n
CHX: ++
(%)
(%)
Lyn118 Lyn118(W99A)
Lyn244 Lyn244(W99A)
Pe
riN
 lo
ca
liz
at
io
n
0
20
40
60
80(%)
Ly
n2
44
Ly
n1
18
Ly
n2
44
(W
99
A)
Ly
n1
18
(W
99
A)
- 41 - 
Figure 9-2
Figure 9. Requirement of the kinase domain in trafficking of Lyn through the Golgi
(A) COS-1 cells transfected with Lyn118-GFP, Lyn118(W99A)-GFP, Lyn244-GFP, and Lyn244(W99A)-GFP 
werer cultured for 18 h and stained with PI. (B) COS-1 cells transfected with Lyn-GFP or Lyn244-GFP 
(lacking the kinase domain) were cultured for 15 h, subsequently treated with 200 µg/ml of cycloheximide 
(CHX) for 3 h at 37ºC or 19ºC and stained with anti-caveolin antibody. Insets show fluorescence images of 
caveolin (red). Results (%) of Golgi localization of Lyn mutants are shown from three independent 
experiments. Results in the absence of CHX (Control) were obtained from two independent experiments. 
Arrows indicate the Golgi region. (C) COS-1 cells were cotransfected with Lyn∆K-GFP plus Lyn-HA were 
cultured for 18 h and stained with anti-HA antibody (red). Magnified images of the squared area are shown in 
insets. All Z-series sections at 0.3-0.5 µm intervals were merged in two-dimensional xy images. Orthogonal 
sections viewing axial directions (xz and yz) are created in the margins. Arrowheads indicate the area where 
Lyn-HA is minimally colocalized with Lyn∆K-GFP. Scale bars, 20 µm.
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Figure 10
Figure 10. Colocalization of Lyn, but not Lyn∆K, with the Golgi caveolin
(A and B) Cells transfected with Lyn-HA (A) and Lyn∆K-HA (B) were cultured for 18 h and stained with 
anti-HA (green) and anti-caveolin (red) antibodies. Orthogonal sections viewing axial directions (xz and yz) 
at the lines are created in the margins. Arrowheads indicate the area where Lyn∆K is minimally colocalized 
with Golgi caveolin. Scale bars, 20 µm.
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Conclusion 
 
   This work shows that N-terminal lipid modifications and the kinase domains of Lyn are 
important factors in regulation of the trafficking of Lyn to the nucleus or the Golgi apparatus 
(Fig. 11). Once newly synthesized Lyn is myristoylated in the cytoplasm, Lyn is targeted to 
the Golgi region and subsequently translocated to the plasma membrane. In addition to the 
lipid modification, the kinase domain of Lyn is required for the Golgi targeting and 
trafficking of Lyn. In contrast, lipid modication of Lyn inhibits the distribution of Lyn to the 
nucleus. Nucleocytoplasmic distribution of Lyn is regulated through import into and rapid 
export from the nucleus. Anchor to membranes through the lipid modification of Lyn and the 
level of its kinase activity contribute to the nucleocytoplasmic distribution of Lyn.  
   The regulation of Lyn trafficking to the nucleus or the Golgi region must be critical for its 
function such as response to DNA damage in the nucleus and response to oxidative stress at 
the Golgi region. Further investigation of a relevant binding protein to Lyn will help us to 
understand the spatiotemporal regulation of Lyn function. 
 
Figure 11. Trafficking of Lyn tyrosine kinase to the nucleus and the Golgi 
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